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Objectives: Impaired clearance of dying and dead cells by professional and amateur 
phagocytes plays a crucial role in the etiology of systemic lupus erythematosus (SLE). 
While dying, cells expose and release a plethora of eat-me and find-me signals to ensure 
their timely removal before entering the dangerous stage of secondary necrosis. A well- 
described chemoattractant for macrophages is dying cell-derived lysophosphatidylcho-
line (LPC). However, its implications for and/or its association with SLE disease, so far, 
have not been examined. In the present study, we analyzed the LPC serum concentra-
tions of patients with SLE and rheumatoid arthritis (RA). Subsequently, we examined 
if and to which extent the measured serum concentrations of LPC and an LPC-rich 
environment can impact the phagocytosis of necrotic cells.
Methods: Sera from patients with SLE, RA, and normal healthy donors (NHD) were 
characterized for several parameters, including LPC concentrations. Phagocytosis of 
dead cells by human macrophages in the presence of SLE and NHD sera was quanti-
fied. Additionally, the impact of exogenously added, purified LPC on phagocytosis was 
analyzed.
results: Patients with SLE had significantly increased LPC serum levels, and high serum 
LPC of SLE patients correlated significantly with impaired phagocytosis of dead cells in 
the presence of heat-inactivated serum. Phagocytosis in the presence of sera from NHD 
showed no correlation to LPC levels, but exogenous addition of purified LPC in the range 
as measured in SLE patients’ sera led to a concentration-dependent decrease.
conclusion: Our data show that high levels of LPC as observed in the sera of SLE 
patients have a negative impact on the clearance of dead cells by macrophages. 
Chemoattraction requires a concentration gradient. The higher the LPC concentration 
surrounding a dying or dead cell, the smaller the achievable gradient upon LPC release 
Table 1 | Demographics of the cohorts studied.






n 25 20 50
Sex M/F 13/12 13/7 5/45
Mean age (years) 31.5 ± 7.3 49.8 ± 17.8 43.2 ± 14.0
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will be. Thus, it is feasible to assume that elevated LPC levels can interfere with the 
build-up of a local LPC gradient during cell death, and hence might play a role in the 
establishment and/or perpetuation of SLE disease.
Keywords: systemic lupus erythematosus, rheumatoid arthritis, efferocytosis, lysophosphatidylcholine, 
phagocytosis, necrotic cells, serum, clearance deficiency
and macrophages with involvement of the G protein-coupled 
receptor G2A (21–24). Intriguingly, mice with genetic deletion 
of G2A develop a late-onset multi-organ autoimmune condition, 
which closely resembles human SLE (25), suggesting that interfer-
ence with the LPC-G2A axis—presumably via disturbed phago-
cyte recruitment during efferocytosis—favors the development of 
autoimmunity. Therefore, the question arises if patients with auto-
immune diseases display alterations in the LPC–G2A axis. To date, 
this has not been studied systematically. Previously, we performed 
transcriptomic profiling analyses in peripheral blood monocytes 
of SLE patients. G2A was among the examined candidate genes, 
but we did not detect any significant alterations in the SLE group 
in comparison to normal healthy donors (NHD) (26).
In the present study, we focused on LPC and analyzed the corre-
sponding serum levels in SLE patients, patients with rheumatoid 
arthritis (RA), and NHD. We observed significantly increased 
LPC serum levels in the SLE group and particularly high levels in 
patients with involvement of vessels or kidneys, respectively. Since 
this can be a cause as well as a consequence of impaired effero-
cytosis, we next examined dead cell phagocytosis in the presence 
of SLE sera and in the presence of NHD sera supplemented with 
LPC concentrations that have been observed in the SLE group. 
A significant correlation of elevated LPC levels with impaired 
phagocytosis of dead cells in the presence of heat-inactivated SLE 
sera was detected and further confirmed by exogenous addition 
of purified LPC to NHD sera. Accordingly, we conclude that 
increased LPC levels can interfere with local dead cell-derived 
LPC, which functions as a phagocyte attraction signal. This might 
contribute to the impairment of clearance and consequently to the 
establishment and/or maintenance of SLE disease.
PaTienTs anD MeThODs
Patients
We obtained sera from patients with SLE visiting our inpatient 
and outpatient departments. Demographic and clinical data 
available in 50 patients with SLE were summarized together with 
routine serology in Tables  1 and 2. Serologic parameters were 
measured in our routine laboratory immediately after blood 
drawing. Disease activity was recorded according to the SLE 
inTrODUcTiOn
The process of apoptotic cell clearance—commonly referred to as 
efferocytosis—works with an impressively high degree of effec-
tiveness and eliminates billions of dying cells in the context of 
tissue homeostasis and cell turnover every day (1). It is so efficient 
that, under physiological conditions, apoptotic corpses are rarely 
to be found. Defects and perturbations in this highly coordinate 
process result in the persistence of cellular debris and have been 
linked to the etiology and pathogenesis of systemic autoimmune 
diseases such as systemic lupus erythematosus (SLE) (2–5). 
Chronic, generalized inflammation, and multi-organ damage are 
the most typical manifestations of SLE (6).
It is widely accepted that uncleared secondary NEcrotic 
cell-derived material (SNEC) in germinal centers of secondary 
lymphatic organs serves as survival and proliferation signal 
for autoreactive B  cells, which will then produce antinuclear 
antibodies (ANAs) in the periphery (7, 8). The co-existence of 
ANAs and accumulated SNEC leads to the formation of immune 
complexes in several tissues (9). This favors a pathological, pro-
inflammatory mode of elimination leading to increased organ 
damage and accumulation of more dying cell debris, thus fueling 
a self-amplifying vicious circle (10). The result is a systemic type 
I interferon signature in response to the ANA–SNEC complexes 
analogous to a viral infection (3, 11).
Clinically, SLE presents as a very heterogeneous autoimmune 
disease with a broad range of manifestations. The prevalence of 
20–150 cases per 100,000 has remained constant in the US in the 
last 20 years (12–14). Adult women are affected seven times more 
often than men and their life expectancy is considerable lower 
than that of the healthy population (15). Typically, the course of 
disease is characterized by remissions and relapses ranging from 
mild to severe with the latter ones also being known as flares (16). 
The classification as SLE of a patient with autoimmune manifesta-
tions is usually done by rheumatologists after meeting at least 4 
out of 13 clinical and serological criteria of the American College 
of Rheumatology (17). Although efferocytosis is closely related 
with the etiopathogenesis of SLE, none of these criteria so far are 
associated with the clearance of dead and dying cells.
In order to attract phagocytes for their timely removal, dying 
cells release soluble find-me signals. Apart from nucleotides, 
the chemokine CX3CL1, sphingosine-1-phosphate, and others, 
lysophosphatidylcholine (LPC) was one of the first dying cell-
derived find-me signals that has been identified (3, 18, 19). 
We and others have shown that the release of LPC during apoptosis 
is orchestrated by caspase-3-mediated cleavage and activation of 
calcium-independent phospholipase A2 (iPLA2), and subsequent 
involvement of the ATP-binding-cassette transporter ABCA1 
(18, 20). Once released, LPC stimulates chemotaxis of monocytes 
Table 2 | Serological and clinical characteristics of the systemic lupus 
erythematosus cohort.
in flare no flare p
serology
n 12 33
CRP, median in mg/dl (IQR) 1.2 (1.7) 0.4 (1.5) 0.189a
C3, median in mg/dl (IQR) 72.5 (37.5) 93.0 (63.0) 0.098a
C4, median in mg/dl (IQR) 10.7 (10.2) 14.2 (10.2) 0.038a
Anti-dsDNA, median in U/ml (IQR) 33.8 (140.2) 11.8 (44.5) 0.097a
Antinuclear antibody titer, median−1 
(IQR)
210.0 (280.0) 320.0 (980.0) 0.518a
APS, n (%) 4 (33.3) 6 (17.1) 0.237b
Treatment
n 12 35
Prednisone median in mg/day (IQR) 7.5 (39.4) 5.0 (10.0) 0.258a
Azathioprine, n (%) 3 (25.0) 15 (42.9) 0.272b
Chloroquine, n (%) 4 (33.3) 13 (37.1) 0.813b
Cyclophosphamide, n (%) 2 (16.7) 2 (5.7) 0.241b
IQR, interquartile range; APS, seropositive antiphospholipid syndrome.
aWilcoxon–Mann–Whitney test.
bChi square test.
Bold font indicates p < 0.05.
FigUre 1 | Multi-step coupled enzymatic test for the detection of lysophosphatidylcholine (LPC). LPC is stepwise converted to glycerophosphocholine, choline, 
and betaine, which eventually is detected in a peroxidase reaction with Amplex Red. Methodologically, baseline fluorescence is recorded by incubating the samples 
with all ingredients except for the first enzyme (lysophospholipase A1) whose addition defines the start of LPC conversion and the value of fluorescence, which is 
subtracted from the final value of fluorescence for calculating the amount of LPC on the basis of a standard curve of purified LPC.
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due to lupus pathology as ascertained by the treating physicians. 
Sera from further 41 patients with SLE, from 20 patients with RA, 
and from 25 NHD were used for the measurement of LPC levels 
(no clinical data available). All patients fulfilled the American 
College of Rheumatology criteria for the classification of SLE 
and RA, respectively (17, 27). A written informed consent was 
obtained from all blood donors and the study received the final 
approval from the ethics committee of the Friedrich-Alexander 
University Erlangen (Permit number 52_14 B).
handling of serum samples
Thirty nine serum samples from patients with SLE and 14 from 
NHD were used for phagocytosis assays in the presence of native 
serum. One aliquot of each serum was treated with heat (56°C) 
for 30 min for complement inactivation (28). Native and heat-
inactivated samples were stored together at −20°C from the day 
of blood withdrawal and thawed once immediately before each 
phagocytosis assay. Additional 15 samples from patients with SLE 
and 4 from NHD were available for phagocytosis assays only in 
form of heat-inactivated serum.
Measurement of serum lPc
Serum LPC concentrations were measured by a multi-step 
coupled enzymatic assay with slight modifications according to 
the protocol described (29). LPC was converted stepwise to glyc-
erophosphocholine, choline, and betaine, which eventually was 
detected in a peroxidase reaction with Amplex Red (Figure 1). 
Disease Activity Index 2000 (SLEDAI-2K) or to the European 
Consensus Lupus Activity Measurement (ECLAM). All patients 
showing disease activity defined as a SLEDAI score of at least 5 or 
as an ECLAM score of at least 4 were considered as in flare. Organ 
involvement was determined by the affection of a specific system 
4Grossmayer et al. LPC Serum Levels in SLE
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Briefly, 20 µl of diluted sera (1:100) were added to 96-well plates, 
250 µl of prewarmed mix A consisting of 100 mM Tris–HCl pH 
8.0, 0.01% Triton X-100, 1 mM calcium chloride, 20 µM Amplex 
Red, 1 U/ml horseradish peroxidase, 0.1 U/ml glycerophospho-
choline phosphodiesterase, 1  U/ml choline oxidase (all from 
Sigma-Aldrich, Taufkirchen, Germany) were added, and baseline 
fluorescence was recorded for 15 min at 37°C in a Synergy Mx 
plate reader (BioTek Instruments, Bad Friedrichshall, Germany) 
at 563 nm excitation and 587 nm emission. Then, the reaction was 
started by adding 75 µl of mix B consisting of 100 mM Tris–HCl 
pH 8.0, 0.01% Triton X-100, and 20  µg/ml lysophospholipase 
A1 (cloned and purified from human THP-1 cells), and Amplex 
Red conversion was recorded over 40  min every minute. LPC 
concentrations were determined from the delta in fluorescence 
with a standard curve of purified LPC (Sigma-Aldrich).
necrotic cells
Necrotic Raji cells served as target cells in our phagocytosis 
experiments. Viable Raji cells were labeled with carboxyfluores-
cein succinimidyl ester-diacetate (CFSE-DA, Molecular Probes, 
Eugene, OR, USA) 1 day prior to the phagocytosis experiments 
according to manufacturer instructions and kept at 37°C 
in 5.5% CO2 atmosphere in complete medium [RPMI 1640 
medium containing 1% l-glutamine (Thermo Fisher Scientific, 
Munich, Germany)], 1% N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (HEPES; Merck, Darmstadt, Germany), 
and 1% penicillin–streptomycin (Thermo Fisher Scientific) 
supplemented with 10% fetal calf serum (FCS, Thermo Fisher 
Scientific). Necrosis was induced immediately before phagocyto-
sis by incubation at 56°C for 30 min. Verification of necrosis was 
done by propidium iodide staining in phosphate-buffered saline 
(PBS) (Thermo Fisher Scientific). More than 99% of the cells were 
positive for propidium iodide.
In Vitro Differentiation of human 
Monocyte-Derived Macrophages (hMDM)
Peripheral blood mononuclear cells (PBMC) of three healthy 
volunteers (blood group 0) were isolated from venous heparin-
ized blood by Ficoll density-gradient centrifugation (Lymphoflot; 
Biotest, Dreieich, Germany). Platelets were depleted by cen-
trifugation through a cushion of FCS. Monocytes were separated 
from PBMC by magnetic cell sorting employing human CD14 
MicroBeads following the manufacturer’s instructions (Miltenyi 
Biotec, Bergisch-Gladbach, Germany) and stained with the car-
bocyanine membrane dyes DiI or DiD (Thermo Fisher Scientific). 
Monocytes were differentiated to HMDM in  vitro either at 
50,000  cells/well (assays with patients’ sera) or 100,000 cells/
well (LPC interference assay) for 7 days at 37°C and 5.5% CO2 
humidified atmosphere in complete medium supplemented with 
10% autologous serum and 10  ng/ml granulocyte-macrophage 
colony-stimulating factor (GM-CSF; Pharmaserv, Marburg, 
Germany). Fresh medium was added at days 3 and 5 after isolation.
Phagocytosis of necrotic cells
Medium from wells containing stained HMDM was removed 
and replaced by 100,000 necrotic Raji cells suspended in 200 µl 
complete medium containing 10% FCS, 10% serum samples 
from SLE patients or healthy controls, 10% autologous serum, 
and varying concentrations of LPC (Sigma-Aldrich), respectively. 
Medium containing up to 0.7% ethanol as LPC-vehicle was used 
as control in phagocytosis assays with added LPC. Phagocytosis 
was allowed for 1 h at 37°C in 5.5% CO2 atmosphere. Adherent 
HMDM were detached by rinsing with cold PBS containing 
2 mM ethylenediamine tetraacetic acid (EDTA; Merck).
Flow cytometry and Data Management
The uptake of necrotic cells by HMDM was monitored by two-
color flow cytometry. HMDM were identified by size and by 
positive staining for DiI or DiD. HMDM being double-positive 
for CFSE and DiI or DiD, respectively, were considered to have 
ingested necrotic cells, which was further confirmed by confocal 
laser microscopy as reported previously (30). The phagocytosis 
index (PhIx) was calculated as the standardized product of the 
percentage of double-positive HMDM and the mean CFSE 
fluorescence intensity (relative amount of engulfed material) of 
double-positive HMDM. Experiments with patients’ sera were 
carried out in duplicates and assays with exogenously added 
LPC in triplicates. Standardization enabled fusion of results from 
different days and dyes and was achieved by normalizing the 
measured PhIx to phagocytosis in the absence of human serum 
of each experiment. In the LPC titration assays, normalization 
was done by defining the PhIx of the LPC-free samples as 100%.
statistical analyses
Statistical analyses were performed using Prism 5 for Windows 
(GraphPad Software, Inc., La Jolla, CA, USA) or SPSS Statistics 
21 (IBM Corp., Armonk, NY, USA), respectively. Correlations 
were calculated according to the non-parametric Spearman algo-
rithm. For comparisons between groups, normal distribution was 
confirmed by Kolmogorov–Smirnov tests followed by two-sided 
Student’s t-tests. If normality was rejected, group comparisons 
were performed by two-sided Wilcoxon–Mann–Whitney tests. 
Independence of variables was examined by Chi square tests. 
Levels of p < 0.05 were considered as statistically significant.
resUlTs
In order to examine if SLE patients display alterations in LPC 
serum levels and if this might be of functional relevance for prey 
cell engulfment, we established a multi-step enzymatic test for 
the detection of LPC and applied the sera to in vitro phagocytosis 
assays with HMDM and dead Raji cells.
sle Patients exhibit increased levels  
of serum lPc
The mean LPC serum concentration in the group of NHD 
as measured by the multi-step coupled enzymatic test was 
886 ± 493.3 µM. In comparison, patients with SLE had signifi-
cantly increased LPC serum levels (1,298 ± 687.9 µM; p = 0.0132; 
after Dunn’s correction p < 0.05). No significant differences were 
observed when comparing RA patients (953.1  ±  233.4  µM) 
with NHD or with SLE patients, respectively (Figure 2). To our 
FigUre 2 | Lysophosphatidylcholine (LPC) serum levels of patients with 
systemic lupus erythematosus (SLE) are elevated. In serum samples of 
normal healthy donors (NHD), patients with rheumatoid arthritis (RA) and SLE 
LPC concentrations were analyzed by a multi-step coupled enzymatic test as 
depicted in Figure 1. LPC levels from individual serum samples, their means, 
and SDs are shown. Open symbols (only LPC values available), filled symbols 
(LPC values and phagocytosis index available), bold bars (cohort means), thin 
bars (cohort SDs).
Table 3 | Serum concentrations of LPC and phagocytosis of necrotic cells in inactive serum stratified by organ involvement in patients with systemic lupus 
erythematosus.
Organ involvement n (%) lPc (µM)  
Mean ± sD
p Phix  
Mean ± sD
p
Vessels Yes 6 (12.5) 1,561.7 ± 519.0 0.036 295.1 ± 104.4 0.051
No 42 (87.5) 952.2 ± 660.4 427.8 ± 190.1
Kidney Yes 16 (33.3) 1,322.4 ± 715.5 0.030 371.3 ± 166.9 0.137
No 32 (66.7) 881.3 ± 607.0 433.0 ± 194.8
APS Yes 10 (20.0) 1,091.1 ± 653.4 0.760 427.1 ± 119.8 0.386
No 40 (80.0) 1,013.9 ± 672.8 407.6 ± 200.8
Skin Yes 25 (52.1) 1,107.9 ± 648.2 0.398 414.2 ± 178.2 0.459
No 23 (47.9) 941.9 ± 699.3 408.6 ± 198.9
Joints Yes 18 (37.5) 998.1 ± 644.5 0.691 406.1 ± 192.1 0.351
No 30 (62.5) 1,078.9 ± 729.7 414.5 ± 186.1
Leukopenia Yes 14 (29.2) 770.0 ± 490.4 0.088 477.2 ± 197.8 0.060
No 34 (70.8) 1,134.6 ± 712.1 385.4 ± 177.5
Central nervous system Yes 6 (12.5) 945.7 ± 812.6 0.751 422.2 ± 130.2 0.448
No 42 (87.5) 1,040.2 ± 659.4 410.4 ± 192.7
Serosal membranes Yes 11 (22.9) 926.2 ± 529.0 0.571 455.8 ± 247.3 0.189
No 37 (77.1) 1,058.7 ± 711.5 398.8 ± 166.5
LPC, lysophosphatidylcholine; PhIx, phagocytic index; APS, seropositive anti-phospholipid syndrome.
Bold font indicates p < 0.05
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levels of serum complement C4 (in flare median: 10.7  mg/dl; 
no flare median 14.2  mg/dl; p =  0.038). The concentration of 
serum LPC was slightly elevated in patients with flares, but this 
difference did not reach statistical significance (not shown). We 
observed particularly high LPC serum levels in patients with 
vessel (p = 0.036) and kidney (p = 0.030) involvement (Table 3). 
Unfortunately, no complete data on renal function were available. 
Five out of 16 patients with renal involvement showed severely 
compromised renal function as manifested by high protein levels 
in urine and creatinine clearance lower than 50  ml/min (not 
shown), but no significant association with LPC serum levels was 
detected. Interestingly, serum LPC levels correlated significantly 
and inversely (p = 0.014) with antinuclear antibody (ANA) titers 
in patients with SLE (Figure 3). No other statistical association 
with laboratory parameters (Tables 1 and 2) or prednisone treat-
ment was found (not shown).
Destruction of heat-labile serum 
components reveals the Distinct effect  
of Thermostable Factors on Phagocytosis 
of necrotic cells In Vitro
In a first step to address the potential association of serum LPC 
levels with the process of dying cell clearance and SLE disease, 
we analyzed the effects of NHD and SLE sera in their native and 
heat-inactivated form on the phagocytosis of necrotic cells by 
HMDM (Figure 4). The uptake of necrotic cells was quantified by 
the PhIx. Phagocytosis in the presence of native sera from NHD 
(13.9 ± 4.3) was similar to that in the presence of native sera from 
patients with SLE (13.2 ± 4.7). In order to eliminate the influ-
ence of heat-labile serum factors on phagocytosis and to focus 
on the effects of thermally stable components (like LPC), sera 
were heat inactivated at 56°C for 30 min. This strongly reduced 
the uptake of necrotic cells in comparison to native serum in 
the NHD (p < 0.0001) as well as the SLE (p < 0.0001) cohort, 
knowledge, this is the first detailed report about concentrations 
of LPC in sera of patients with SLE.
Demographical, serological, and clinical 
characteristics of the sle cohort
Clinical and serological information about SLE patients are 
shown in Tables 1 and 2. Considering the actual clinical activity 
status of the patients, we observed that patients in flare (SLEDAI 
score ≥5 or ECLAM score ≥4, Table 2) showed significantly lower 
FigUre 4 | Influence of heat-labile serum components on the phagocytosis 
of necrotic cells by human monocyte-derived macrophages. Uptake of 
necrotic cells was analyzed by flow cytometry and quantified by the 
phagocytosis index (PhIx). Phagocytosis was allowed in the presence of 
native or heat-inactivated (56°C for 30 min) serum from normal healthy 
donors (NHD) or patients with systemic lupus erythematosus (SLE). 
Phagocytosis in heat-inactivated serum was lower in both cohorts than in 
native serum (NHD and SLE each p < 0.0001). There was no significant 
difference in phagocytosis between the NHD and SLE cohort neither in native 
serum nor in heat-inactivated serum. Open symbols (only PhIx available), 
filled symbols (PhIx and lysophosphatidylcholine concentration available), 
bold bars (cohort means), thin bars (cohort SDs).
FigUre 3 | Lysophosphatidylcholine (LPC) serum levels of patients with 
systemic lupus erythematosus inversely correlated with antinuclear antibody 
(ANA) titers. Correlation analysis of serum LPC values and ANA titers. The 
values of ANA titers and serum LPC concentrations were transformed to rank 
values, and the Spearman rho correlation coefficient was calculated 
(p = 0.014 after Bonferroni correction).
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similar levels of phagocytosis, and no significant difference in 
PhIx was observed.
serum lPc levels of sle Patients 
negatively correlate with Phagocytosis  
of necrotic cells In Vitro
In the next step, we analyzed the relationship between serum 
LPC concentrations and phagocytosis as quantified by the PhIx. 
No significant correlation was observed in case of native sera, nei-
ther in the NHD (not shown) nor in the SLE group (Figure 5A). 
In line with our previous findings and reports by others, comple-
ment C4 and ANA titers revealed significant correlations with 
phagocytosis in native serum (not shown) (30). Upon heat 
inactivation, the impact of thermosensitive components, includ-
ing complement, is eliminated, and the influence of thermostable 
serum factors on the engulfment process can be examined. LPC 
belongs to the group of thermostable serum components due to 
its lipid nature. Whereas phagocytosis in the presence of heat-
inactivated serum from NHD showed no significant association 
with LPC concentrations (not shown), a highly significant nega-
tive correlation (r = –0.556, p < 0.0001) between LPC levels and 
phagocytosis in case of heat-inactivated serum from patients with 
SLE was observed (Figure 5B).
We also performed group comparisons for all organ involve-
ment groups. Sera from patients with kidney or vessel involve-
ment with particularly high LPC levels displayed a tendency 
toward reduced phagocytosis activity. However, this did not reach 
statistical significance. In turn, sera from patients with leukopenia 
showed particularly low LPC levels and a trend toward increased 
phagocytosis activity (Table  3). This underlines the negative 
relationship between LPC serum concentration and phagocytosis 
activity and raises the question of causality.
exogenously added lPc reduces 
Phagocytosis of necrotic cells In Vitro
As a first approach to analyze the causality between high serum 
LPC levels and decreased uptake of necrotic cells, NHD serum 
was supplemented with increasing concentrations of purified 
LPC (in the range that was measured in the SLE sera). Figure 6 
compares the phagocytosis results of LPC supplementation 
versus the corresponding vehicle control. All PhIxs were nor-
malized to the PhIx value of the original serum (added LPC 
concentration = 0 mM). Addition of LPC resulted in a significant 
concentration-dependent decline in phagocytosis in native serum 
(p < 0.0001) as well as in heat-inactivated serum (p = 0.0027) in 
comparison to the LPC-free control (Figures 6A,B). The phago-
cytosis of necrotic cells was similarly inhibited by LPC to 35% in 
native and to 34% in heat-inactivated serum. The vehicle control 
showed no influence on phagocytosis, neither in native nor in 
heat-inactivated serum.
DiscUssiOn
Billions of cells die in the context of normal tissue regeneration 
every day. If they are not cleared in time, the process of death 
enters the stage of secondary necrosis and SNEC accumulate in 
respectively—most likely due to inactivation of complement and 
other heat-sensitive opsonins. Again, addition of inactivated sera 
from NHD (4.3 ± 1.5) and SLE patients (4.1 ± 1.9) resulted in 
FigUre 6 | Exogenously added lysophosphatidylcholine (LPC) reduces phagocytosis of necrotic cells in vitro. Normal healthy donor serum was supplemented with 
the indicated concentrations of purified LPC, added to phagocytosis assays with necrotic cells in its native or heat-inactivated form, and phagocytosis was 
measured as % of unsupplemented serum (100% control). (a) Data for native serum. (b) Data for heat-inactivated serum. The addition of LPC resulted in a 
significant concentration-dependent decline in phagocytosis in comparison to the LPC-free control (two-way ANOVA test). Means ± SEs of triplicates are shown.
FigUre 5 | Serum lysophosphatidylcholine (LPC) levels of systemic lupus erythematosus (SLE) patients correlate negatively with phagocytosis of necrotic cells 
in vitro. Serum LPC levels of SLE patients were correlated to phagocytosis of necrotic cells in the presence of the respective serum as determined by the 
phagocytosis index (PhIx). Each data point represents an individual serum value. (a) Phagocytosis assays in the presence of native serum. n.s., not significant.  
(b) Phagocytosis assays in the presence of heat-inactivated serum. Dashed lines indicate the 95% confidence interval.
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peripheral tissues (3). Pioneering experimental evidence for the 
existence of this kind of non-engulfed cellular debris in tissue 
samples from patients with SLE was already provided in the 
late 1950s (31). Several studies reported so-called hematoxylin 
bodies defined as exclusively extracellular, single, clustered, or 
coalescent corpses found specifically in tissues of 70–90% of 
virtually untreated patients with SLE (32–35). Regrettably, at that 
time, these alterations could not be associated with cell death 
phenomena, because apoptosis was firstly described much later 
(36). More recently, increased amounts of apoptotic PBMC and 
neutrophils have been reported in patients with SLE (37, 38). 
The process of apoptosis itself turned out not to be affected (39). 
Instead, an engulfment dysfunction was identified as the underly-
ing reason for the accumulation of uncleared, dead cell material 
in patients with SLE (40).
In the course of apoptosis, the plasma membrane of cells 
undergoes characteristic changes. Whereas viable cells exhibit 
a clear membrane phospholipid asymmetry, during apoptosis, 
redistribution of phospholipids between the membrane leaflets 
occurs (41, 42). Moreover, phospholipases (PLA2) generate LPC 
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by hydrolyzing the fatty acid at the sn-2 position of glycerophos-
pholipids (43–45). Calcium-independent phospholipase A2 
(iPLA2) is processed during apoptosis by caspase-3-mediated 
cleavage leading to a truncated form with increased activity (46), 
and LPC appears to be the major product of lipid catabolism 
in apoptotic cells (45, 47). Its release under participation of the 
membrane transporter ABCA1 and its role as chemoattractant in 
the clearance of dead cells has been confirmed by us and others 
(18, 21, 24).
In the present study, we observed increased LPC levels in 
sera of patients with SLE, and the highest levels were detected 
in patients with vessel or kidney involvement (Figure  2). 
In principle, elevated serum LPC levels could be a cause as well 
as a consequence of SLE disease. It is feasible to assume that 
accumulating dying cell material due to known clearance defi-
ciencies in SLE could give rise to accumulation of LPC in organs 
and tissues, which might finally “spill over” into the serum. This 
might be particularly strong in case of vasculitis since, here, cell 
death occurs in very close proximity to the blood. In case of 
kidney involvement, renal dysfunction and impaired lipid clear-
ance might additionally contribute to the increase in LPC serum 
levels as has been reported in the context of type II diabetes and 
renal transplantation (48, 49). Vice versa, elevated LPC serum 
levels could affect dying cell clearance by interfering with proper 
phagocyte recruitment leading to delays in dying cell clearance 
and establishment as well as maintenance of SLE disease.
Lysophosphatidylcholine is a potent find-me signal of dying 
cells (50–53), provided that a concentration gradient between 
the dying/dead cell and the phagocyte can be established. 
Experimental neutralization of this gradient by adding exog-
enous LPC can efficiently interfere with chemoattraction of 
THP1-monocytes by supernatants of apoptotic cells (21), and 
sera from patients with SLE reportedly reduce chemoattraction of 
macrophages by supernatants of apoptotic cells (54). In contrast, 
NHD sera or sera from RA patients show no inhibition of phago-
cyte migration (54). Hence, the elevated LPC levels in SLE sera 
reported here might be the reason for the inhibition of chemoat-
traction in our previous study (54). Along the same lines, we now 
observed a significant correlation between high LPC levels in SLE 
sera and interference with phagocytosis of dead cells, but only 
in case of heat-inactivated sera, where the influence of ANAs, 
antiphospholipid antibodies, complement factors, and other 
heat-labile opsonins has been minimized (Figure  5B). ANAs, 
antiphospholipid antibodies, and complement factors are well-
known to affect the internalization of dying cells, and their titers 
can vary strongly in sera of SLE patients (55–58). In turn, heat-
inactivation of serum allows studying the phagocytic impact of 
heat-stable compounds, including LPC. This might be specifically 
relevant in tissues where the concentration of serum proteins is 
low. It should be noted that we observed this correlation between 
high LPC serum levels and interference with phagocytosis of 
dead cells only in SLE but not in NHD sera. Further subgroup 
analyses revealed that the correlation was particularly strong for 
LPC serum levels >1 mM (not shown). This might explain why 
no significant correlation for NHD sera (mean LPC concentra-
tion 886 ± 493.3 µM) was observed and suggests that a certain 
type of threshold does exist in this regard. Detailed analyses of 
the groups with different organ involvements revealed trends 
of high serum LPC levels and low phagocytosis activity in case 
of kidney and vessel involvement as well as low serum LPC level 
and high phagocytosis activity in case of leukopenia. Although 
these trends did not reach statistical significance, they argue in 
favor of a negative relationship between increased serum LPC 
concentrations and phagocytic activity.
Evidence for the causal involvement of LPC in phagocytosis 
inhibition derives from our add-in experiments: NHD serum sup-
plemented with increasing concentrations of purified LPC ham-
pered dead cell phagocytosis in an LPC concentration-dependent 
manner irrespective if it was heat-inactivated or not (Figure 6). 
Of note, the add-in phagocytosis experiments were performed 
with NHD serum which—in contrast to SLE sera—is of rather 
constant composition and lacks relevant titers of autoantibodies. 
This represents a plausible explanation why addition of LPC to 
native and inactivated NHD serum had similar effects on phago-
cytosis, while the correlation between LPC levels in SLE sera and 
phagocytic activity was only measurable upon heat inactivation.
Interestingly, we observed higher LPC serum levels in patients 
with flare than patients with non-flare. Although this trend was 
statistically not significant, it might be speculated that elevated 
levels of LPC function as a clearance inhibitor at a cellular level 
and lead to SLE disease exacerbation ensuing from reduced 
efferocytosis, augmented release of autoantigens, and immune 
complex formation, and resulting in enforced inflammatory 
conditions and clinical symptoms.
Eat-me signals presented on the membrane surface require 
a direct cell–cell contact in order to be functional. In contrast, 
find-me signals are released from dying and dead cells and oper-
ate over a certain distance [reviewed in Ref. (59)]. The existence 
of a chemotactic concentration gradient is a prerequisite for the 
attraction and migration of phagocytes. Under non-pathological 
conditions (as is the case in the presence of NHD sera), local 
gradients of find-me signals can be successfully built up around a 
dying cell (Figure 7A). Macrophages follow the gradient until they 
encounter dying cells and then can recognize and engulf them via 
exposed eat-me signals. In conditions of abnormally high LPC 
concentrations in the extracellular milieu (as we observed in SLE 
sera and upon supplementation of NHD sera in our phagocytosis 
assays), the LPC amount that is locally released by dying and 
dead cells appears not to be sufficient to establish an effective 
chemotactic gradient (Figure  7B). Consequently, macrophages 
cannot follow the gradient and do not find their way to the dying 
prey. Our data suggest that impaired chemoattraction decreases 
the likelihood of macrophages meeting dead cells, thus resulting 
in the observed decrease in phagocytosis.
Overall, our study is the first to provide experimental evi-
dence for increased serum LPC levels in SLE patients. In vitro, 
this correlated with impaired phagocytosis of dead cells when 
the respective SLE sera were added to phagocytosis assays and 
when NHD sera were supplemented with LPC concentrations in 
the range as measured in SLE sera. Accordingly, we suggest that 
high extracellular LPC levels can neutralize local LPC gradients, 
which are required for phagocyte attraction in the context of 
FigUre 7 | Effect of abnormal high lysophosphatidylcholine (LPC) levels on chemotaxis of macrophages. A local chemotactic concentration gradient is required for 
the attraction and migration of phagocytes toward dying and dead cells. Under non-pathological conditions, an LPC concentration gradient is formed around a 
dying cell (a). Macrophages follow the gradient until they encounter the dying cell and then start the phagocytic process. In conditions with increased extracellular 
LPC concentrations, like we observed in systemic lupus erythematosus (SLE) sera, the amount of LPC released by the dying cell might not be high enough to 
establish a functional chemotactic gradient (b). Macrophages cannot be attracted, they move randomly. The likelihood of contacts between macrophages and 
dying cells is reduced resulting in decreased phagocytosis.
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dying cell clearance, thus contributing to the establishment and/
or perpetuation of SLE disease and rendering serum LPC a poten-
tial, mechanisms-based marker of SLE disease, which deserves 
further validation.
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